The Lancet
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
2022·PMID: 35658024
Jastreboff AM et al.
All Products
Metabolic Research Compound
Tirzepatide
GIP / GLP-1 AgonistDual Incretin Analog
High-purity Tirzepatide peptide for research.
Vial Size
From
$45.00
Bundle & Save
Free shipment protection
We acceptPay
Research use only
Compound Information
Technical specifications
Molecular Profile
What is Tirzepatide?
Dual GIP/GLP-1 receptor agonist studied for metabolic-pathway modulation and weight regulation research.
- Type
- Dual GIP/GLP-1 receptor agonist
- CAS Number
- 2023788-19-2
- Molecular Weight
- 4813.5 g/mol
- Amino Acids
- 39 (modified)
Storage Requirements
Stability Information
Protect from lightAvoid repeated freeze-thaw
Lyophilized (powder)
-20°C·up to 2 years
After opening
2-8°C·use within 30 days
Mechanism of Action
Tirzepatide is a single peptide with balanced agonism at the GIP and GLP-1 receptors. Co-activation produces additive effects on glucose-dependent insulinotropic activity, glucagon suppression, gastric-emptying delay, and central satiety signaling.
Areas of Research
Glycemic control in type-2 diabetes models
Body-mass reduction (SURMOUNT program)
Cardiovascular risk markers
Hepatic steatosis (MASH) research
Purity
≥ 99% by independent third-party HPLC. Endotoxin tested.
Half-Life
~5 days
Solubility
Freely soluble in aqueous diluents
Sources & References
Peer-reviewed research
New England Journal of Medicine
Tirzepatide vs Semaglutide for Type 2 Diabetes (SURPASS-2)
2021·PMID: 34170647
Frías JP et al.
About this compound
Overview
Tirzepatide is a synthetic peptide studied as a dual receptor agonist, acting on both the GIP and GLP-1 receptors. Its dual-receptor profile places it between single agonists and triple agonists in comparative incretin research. PX-Labs supplies Tirzepatide as a lyophilized powder for laboratory research use only.
Background
Incretin-class research peptides are categorized by how many receptors they target. Tirzepatide is studied as a dual GIP/GLP-1 agonist, adding GIP-receptor activity to the GLP-1 activity seen in single agonists such as semaglutide, while triple agonists such as retatrutide add glucagon-receptor activity on top. Researchers comparing receptor activity across the class frequently group these three together.
Specifications
- Compound
- Tirzepatide (dual GIP / GLP-1 receptor agonist)
- Form
- Lyophilized powder, sealed vial
- Purity
- ≥98%, verified by HPLC
- Testing
- Independent third-party analysis; COA available on request
- Available sizes
- 5mg, 10mg
- Presentation
- Lyophilized powder in a sealed research vial
Handling & Storage
In its lyophilized form, Tirzepatide is generally stored refrigerated and protected from light and moisture, with freezer storage common for longer-term holding. Standard laboratory handling practices apply.
Purity & Testing
Every batch is tested to a minimum of 98% purity by high-performance liquid chromatography, with analysis performed by an independent laboratory so results remain impartial. A Certificate of Analysis reporting identity, purity, and method is available on request.
Research Use Only
Tirzepatide is sold strictly for laboratory and scientific research. It is not intended for human or veterinary use, and PX-Labs is a research chemical supplier, not a compounding pharmacy. PX-Labs does not provide usage or application guidance.